EXHIBIT 5

```
1
              UNITED STATES DISTRICT COURT
           FOR THE NORTHERN DISTRICT OF OHIO
2
                    EASTERN DIVISION
    IN RE: NATIONAL
                                    MDL No. 2804
    PRESCRIPTION OPIATE
                                )
                                    Case No.
    LITIGATION
                                    1:17-MD-2804
5
                                ) Hon. Dan A.
    THIS DOCUMENT RELATES TO
                                ) Polster
    ALL CASES
7
8
9
                  Tuesday, May 14, 2019
10
11
       HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
12
                 CONFIDENTIALITY REVIEW
13
14
15
           Videotaped Deposition of JAMES E.
16
     RAFALSKI, VOLUME 2, held at Weitz &
17
     Luxenburg PC, 3011 West Grand Avenue, Suite
     2150, Detroit, Michigan, commencing at
     8:25 a.m., on the above date, before
18
     Michael E. Miller, Fellow of the Academy of
     Professional Reporters, Registered Diplomate
19
     Reporter, Certified Realtime Reporter and
     Notary Public.
20
21
22
23
24
                GOLKOW LITIGATION SERVICES
             877.370.3377 ph | fax 917.591.5672
25
                     deps@qolkow.com
```

1	APPEARANCES:
2	MCHUGH FULLER LAW GROUP
	BY: MICHAEL J. FULLER, ESQUIRE
3	mike@mchughfuller.com
	ALLAN "AJ" ELKINS, JR., ESQUIRE
4	aj@mchughfuller.com
_	AMY QUEZON, ESQUIRE
5	amy@mchughfuller.com
	97 Elias Whiddon Road
6	Hattiesburg, Mississippi 39402 (601) 261-2220
7	Counsel for MDL Plaintiffs
8	Counsel for MDD Flathcills
9	KELLER ROHRBACK LLP
	BY: GARY A. GOTTO, ESQUIRE
10	qqotto@kellerrohrback.com
	3101 North Central Avenue
11	Suite 1400
	Phoenix, Arizona 85012
12	(602) 248-0088
	Counsel for MDL Plaintiffs
13	
14	BRANSTETTER STRANCH & JENNINGS PLLC
	BY: TRICIA HERZFELD, ESQUIRE
15	triciah@bsjfirm.com@bsjfirm.com
	223 Rosa L. Parks Boulevard
16	Suite 200
1,5	Nashville, Tennessee 37203
17	(615) 254-8801 Counsel for Tennessee Plaintiffs
18	Comiser for feminessee traincrits
19	REED SMITH LLP
1 29	BY: ABIGAIL M. PIERCE, ESQUIRE
20	abigail.pierce@reedsmith.com
	1717 Arch Street
21	Suite 3100
	Philadelphia, Pennsylvania 19103
22	(215) 851-8100
	Counsel for AmerisourceBergen Drug
23	Corporation
24	
25	

```
APPEARANCES:
1
         WILLIAMS & CONNOLLY LLP
               STEVEN M. PYSER, ESQUIRE
3
               spyser@wc.com
              BRAD MASTERS, ESQUIRE
4
               bmasters@wc.com
         725 Twelfth Street, N.W.
5
         Washington, D.C. 20005
         (202) 434-5000
6
         Counsel for Cardinal Health Inc.
8
         JONES DAY
         BY: NEAL J. STEPHENS, ESQUIRE
              nstephens@jonesday.com
9
         1755 Embarcadero Road
         Palo Alto, California 94303
10
         (650) 739-3939
11
         Counsel for Walmart Corporation
12
13
         ROPES & GRAY LLP
         BY: ANDREW O'CONNOR, ESQUIRE
               andrew.o'connor@ropesgray.com
14
               WILLIAM DAVISON, ESQUIRE
              william.davison@ropesgray.com
15
         Prudential Tower
         800 Boylston Street
16
         Boston, Massachusetts 02199
17
          (617) 951-7000
         Counsel for Mallinckrodt Pharmaceuticals
18
19
         COVINGTON & BURLING LLP
         BY: CHRISTOPHER K. EPPICH, ESQUIRE
20
               ceppich@cov.com
         1999 Avenue of the Stars
         Los Angeles, California 90067
21
         (424) 332-4800
22
         Counsel for McKesson Corporation
23
24
25
```

```
APPEARANCES:
1
 2
         COVINGTON & BURLING LLP
              MEGHAN MONAGHAN, ESQUIRE
3
               mmonaghan@cov.com
         One City Center
         850 Tenth Street, N.W.
4
         Washington, D.C. 20001
5
          (202) 662-6000
         Counsel for McKesson Corporation
6
7
         LOCKE LORD LLP
         BY: C. SCOTT JONES, ESQUIRE
               sjones@lockelord.com
8
         2200 Ross Avenue
9
         Suite 2800
         Dallas, Texas 75201
10
         (214) 740-8000
         Counsel for Henry Schein, Inc. and
         Henry Schein Medical Systems, Inc.
11
12
13
         FOLEY & LARDNER LLP
         BY: JAMES W. MATTHEWS, ESQUIRE
14
               jmatthews@foley.com
         111 Huntington Avenue
         Boston, Massachusetts 02199
15
          (617) 342-4000
         Counsel for Anda Inc.
16
17
18
         ARNOLD & PORTER KAYE SCHOLER LLP
              DAVID D. FAUVRE, ESQUIRE
         BY:
               david.fauvre@arnoldporter.com
19
         601 Massachusetts Avenue, N.W.
         Washington, D.C. 20001
20
         (202) 942-5000
21
         Counsel for Endo Health
         Solutions Inc., Endo
22
         Pharmaceuticals Inc., Par
         Pharmaceutical, Inc. and Par
23
         Pharmaceutical Companies, Inc.
24
25
```

```
APPEARANCES:
1
2
         KIRKLAND & ELLIS LLP
              ERICA B. ZOLNER, ESQUIRE
3
               erica.zolner@kirkland.com
              KAITLYN L. COVERSTONE, ESQUIRE
              kaitlyn.coverstone@kirkland.com
4
         300 North LaSalle
         Chicago, Illinois 60654
5
         (312) 862-2000
         Counsel for Allergan Finance LLC
6
7
8
         MORGAN LEWIS & BOCKIUS LLP
         BY: MAUREEN K. BARBER, ESQUIRE
              maureen.barber@morganlewis.com
9
         One Oxford Centre
         Thirty-Second Floor
10
         Pittsburgh, Pennsylvania 15219
11
         (412) 560-3300
         Counsel for Teva Pharmaceuticals
         USA Inc., Cephalon Inc., Watson
12
         Laboratories Inc., Actavis LLC, and
         Actavis Pharma Inc. f/k/a Watson
13
         Pharma Inc.
14
15
         ZUCKERMAN SPAEDER LLP
         BY: GRAEME W. BUSH, ESQUIRE
              gbush@zuckerman.com
16
              PAUL B. HYNES, JR., ESQUIRE
17
              phynes@zuckerman.com
              (via teleconference)
18
         1800 M Street, N.W.
         Suite 1000
         Washington, D.C. 20036
19
         (202) 778-1800
20
         Counsel for CVS Indiana LLC and
         CVS Rx Services Inc.
21
22
23
24
25
```

```
APPEARANCES:
1
2
         DECHERT LLP
         BY: ERIK W. SNAPP, ESQUIRE
              erik.snapp@dechert.com
         35 West Wacker Drive
         Suite 3400
         Chicago, Illinois 60601
         (312) 646-5800
5
         Counsel for Purdue Pharma
6
7
         O'MELVENY & MYERS LLP
         BY: AMY R. LUCAS, ESQUIRE
8
              alucas@omm.com
         1999 Avenue of the Stars
9
         8th Floor
         Los Angeles, California 90067
10
         (213) 430-6000
         Counsel for Janssen Pharmaceuticals Inc.
11
12
         MARCUS & SHAPIRA LLP
         BY: JOSHUA A. KORBIN, ESQUIRE
              korbin@marcus-shapira.com
13
         One Oxford Centre
14
         35th Floor
         Pittsburgh, Pennsylvania 15219
         (412) 471-3490
15
         Counsel for HBC Services
16
17
         BARTLIT BECK HERMAN PALENCHAR &
         SCOTT LLP
18
              KATHERINE M. SWIFT, ESQUIRE
         BY:
              katherine.swift@bartlit-beck.com
19
         54 West Hubbard Street
         Suite 300
         Chicago, Illinois 60654
20
         (312) 494-4400
         Counsel for Walgreens Company
21
22
23
24
25
```

```
APPEARANCES:
 1
         BARNES & THORNBURG LLP
         BY: WILLIAM LEEDER, ESQUIRE
 3
               bill.leeder@btlaw.com
         171 Monroe Avenue, N.W.
         Suite 1000
 4
         Grand Rapids, Michigan 49503
 5
          (616) 742-3930
         Counsel for H.D. Smith
 6
7
         CAVITCH FAMILO & DURKIN CO. L.P.A.
         BY: ERIC J. WEISS, ESQUIRE
               eweiss@cavitch.com
8
               (via teleconference)
9
         1300 East 9th Street
         Cleveland, Ohio 44114
10
          (216) 621-7860
         Counsel for Discount Drug Mart
11
12
         FOX ROTHSCHILD LLP
         BY: STEPHAN A. CORNELL, ESOUIRE
13
               scornell@foxrothschild.com
              (via teleconference)
         2700 Kelly Road
14
         Suite 300
         Warrington, Pennsylvania 18976
15
          (215) 345-7500
16
         Counsel for Prescription Supply Inc.
17
18
         MORGAN LEWIS & BOCKIUS LLP
         BY: CAROLYN A. SILANE, ESQUIRE
19
               carolyn.silane@morganlewis.com
               (via teleconference)
20
         101 Park Avenue
         New York, New York 10178
21
          (212) 309-6000
         Counsel for Rite Aid
22
23
     VIDEOGRAPHER:
24
           David Lane,
           Golkow Litigation Services
25
```

Case: 1917-ynd-02294-DAP: Dpc#: 1914-7cFiled: P7/19/19-9c6-15: Page 12#: 1935-5eview

		**
1	INDEX	
2		
3	APPEARANCES	412
	PROCEEDINGS	421
4		
5		
6	EXAMINATION OF JAMES E. RAFALSKI:	
7	BY MS. SWIFT	421
8	BY MR. BUSH	562
9	BY MR. O'CONNOR	630
10	BY MS. LUCAS	703
	BY MS. ZOLNER	740
11	BY MR. SNAPP	776
12	BY MR. FAUVRE	794
13	BY MS. BARBER	810
14	BY MR. FULLER	829
15	BY MR. MATTHEWS	838
16		
17		
18	CERTIFICATE	842
19	ERRATA	845
20	ACKNOWLEDGMENT OF DEPONENT	846
21	LAWYER'S NOTES	847
22		
23		
24 25		
1		

1	PROCEEDINGS
2	(May 14, 2019 at 8:25 a.m.)
3	THE VIDEOGRAPHER: We're now on
4	the record. My name is David Lane,
5	videographer for Golkow Litigation
6	Services. Today's date is May 14th,
7	2019. Our time is 8:25 a.m.
8	This deposition is taking place
9	in Detroit, Michigan in the matter of
10	National Prescription Opiate
11	Litigation. Our deponent today is
12	James E. Rafalski. Counsel will be
13	noted on the stenographic record.
14	Our court reporter today is
15	Mike Miller.
16	Mr. Rafalski, I just want to
17	remind you, you're still under oath
18	from yesterday.
19	THE WITNESS: Yes, sir, I
20	understand. Thank you.
21	EXAMINATION
22	BY MS. SWIFT:
23	Q. Good morning, Mr. Rafalski.
24	A. Good morning.
25	Q. We met a moment ago. My name

- 1 effective controls. Falling under that is
- suspicious order system.
- Q. So the list on 37 to 40, these
- 4 are not requirements under 1301.74(b), the
- suspicious order monitoring regulation,
- 6 correct?
- 7 A. So I'd like to answer that by
- 8 saying I believe these are all components,
- 9 which would be necessary to have an effective
- 10 suspicious monitoring -- a suspicious order
- 11 monitoring system.
- Q. And with respect, sir, that's
- 13 not what I asked you.
- 14 Are the bullet list components
- on pages 37 to 40 of your report required
- under 1301.74(b), the suspicious order
- monitoring --
- A. Yes, they are.
- Q. Okay. All of them?
- 20 A. Yes.
- Q. Okay. Great. Thanks.
- Is it possible to have a
- compliant suspicious order monitoring system
- without all of these components?
- A. Yes, I think it would be

```
1
     possible.
2
                   But they are all requirements?
            Ο.
3
                   Based on -- depending on the
            Α.
4
     scope of the business that's the customer and
     based on the scope of activity of the
5
6
     distributor, I would say that some of
     these -- there could be some of these that
7
8
     would not be necessary. But I'd also say
9
     that there may be some that aren't identified
10
     on this list. And also, based on the fact
11
     that the distribution activity is not static
12
     and it changes.
13
                   So if I'm following you, all of
14
     the bullet-listed components on pages 37 to
     40 are, in fact, required under 1301.74(b),
15
16
     but you could have a compliant suspicious
17
     order monitoring system without all of these
18
     compliant -- components, and, in fact, there
19
     may be other components that are required
20
     under 1301.74(b) that are not included in
21
     this list.
                   Do I have all that, correct,
22
23
     sir?
24
                   I believe that's correct, yes.
           Α.
25
                   Okay.
            Q.
```

- 1 A. I'm not saying this is an
- exclusive list and there might not be other
- 3 things that I have not considered or might
- 4 come up based on the type of business
- 5 activities that are involved.
- Q. On page 39, if you would take a
- 7 look, please. You say, the top bullet, that:
- 8 A robust and well-documented due diligence
- 9 program is key.
- And then it goes on from there
- and provides components that you say you
- would like to see in a due diligence
- compliance program for suspicious orders,
- 14 correct, sir?
- A. Yes, ma'am.
- Q. Is it your opinion that a
- distributor has to do all of the diligence
- steps listed here in order to comply with the
- 19 law?
- A. Yes, ma'am.
- Q. All right. I want you to hold
- on to these pages of your report for a
- minute, please. And I'm going to hand you a
- document. This will be Exhibit 19.
- 25 (Whereupon, Deposition Exhibit

1 Yes, there could be. Α. 2 And those other methods that Q. 3 are not identified in your report might be perfectly sufficient for identifying 4 suspicious orders, correct, sir? 5 6 Α. I hope for the sake of 7 diversion they are perfect and they do exist, 8 but yes, that's a possibility. 9 And, in fact, you testified Q. 10 yesterday, I believe, that it's up to the 11 registrant to design a system that makes 12 sense for that registrant's business, 13 correct, sir? 14 Α. That's correct. 15 Q. When you were at the DEA, you 16 never advised a registrant to follow any of 17 the five flagging methods that are addressed 18 in your report, correct, sir? 19 MR. FULLER: Same instruction 20 on Touhy. 21 MS. SWIFT: Are you going to 22 follow your counsel's instruction not 23 to answer that question, sir? THE WITNESS: I'd like to think 24 25 about it first. Is that okay?

1 CERTIFICATE 2 I, MICHAEL E. MILLER, Fellow of the Academy of Professional Reporters, Registered Diplomate Reporter, Certified 3 Realtime Reporter, Certified Court Reporter and Notary Public, do hereby certify that 4 prior to the commencement of the examination, JAMES E. RAFALSKI was duly sworn by me to 5 testify to the truth, the whole truth and nothing but the truth. 6 7 I DO FURTHER CERTIFY that the foregoing is a verbatim transcript of the testimony as taken stenographically by and 8 before me at the time, place and on the date hereinbefore set forth, to the best of my 9 ability. 10 I DO FURTHER CERTIFY that pursuant 11 to FRCP Rule 30, signature of the witness was not requested by the witness or other party before the conclusion of the deposition. 12 13 I DO FURTHER CERTIFY that I am neither a relative nor employee nor attorney nor counsel of any of the parties to this 14 action, and that I am neither a relative nor employee of such attorney or counsel, and 15 that I am not financially interested in the 16 action. 17 18 MICHAEL E. MILLER, FAPR, RDR, CRR Fellow of the Academy of Professional Reporters 19 NCRA Registered Diplomate Reporter NCRA Certified Realtime Reporter 20 Certified Court Reporter 21 Notary Public 22 My Commission Expires: 7/9/2020 Dated: May 15, 2019 23 24 25